Tudor Investment Corp ET AL Makes New Investment in Liquidia Corporation $LQDA

Key Points

• Tudor Investment Corp ET AL opened a new position in Liquidia (NASDAQ:LQDA) in Q3, buying 67,557 shares worth about $1.54 million and representing roughly 0.08% ownership; overall institutional and hedge fund ownership stands at 64.54%.
• Analyst sentiment is mostly positive with an average rating of "Moderate Buy" and a $43.44 average price target, and Liquidia recently posted an EPS beat ($0.15 vs. $0.08) and $92.0M revenue despite negative net margin and return on equity.

Tudor Investment Corp ET AL bought a new position in Liquidia Corporation (NASDAQ:LQDA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 67,557 shares of the company's stock, valued at approximately $1,536,000. Tudor Investment Corp ET AL owned 0.08% of Liquidia at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the second quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia in the third quarter worth about $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia in the third quarter worth about $34,000. Tower Research Capital LLC TRC boosted its holdings in shares of Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock worth $83,000 after buying an additional 4,927 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Liquidia in the third quarter worth about $170,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on LQDA. Wall Street Zen upgraded shares of Liquidia from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Lifesci Capital raised shares of Liquidia to a "strong-buy" rating in a research report on Thursday, March 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Liquidia in a research report on Thursday, January 22nd. Jefferies Financial Group increased their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, January 13th. Finally, Needham & Company LLC increased their price target on shares of Liquidia from $52.00 to $54.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $43.44.

Liquidia Price Performance

NASDAQ LQDA opened at $38.55 on Monday. The company has a 50 day simple moving average of $36.98 and a 200-day simple moving average of $32.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -46.45 and a beta of 0.45. Liquidia Corporation has a 52-week low of $11.85 and a 52-week high of $46.67.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. Liquidia's revenue for the quarter was up 3072.4% compared to the same quarter last year. Equities research analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In related news, insider Scott Moomaw sold 18,314 shares of the firm's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $36.79, for a total transaction of $673,772.06. Following the transaction, the insider owned 187,640 shares of the company's stock, valued at approximately $6,903,275.60. This trade represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Dana Boyle sold 1,580 shares of the firm's stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $41.65, for a total transaction of $65,807.00. Following the transaction, the chief accounting officer directly owned 178,848 shares in the company, valued at approximately $7,449,019.20. The trade was a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 83,132 shares of company stock worth $3,016,281 in the last ninety days. Insiders own 30.10% of the company's stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.